Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: A longitudinal study

Diabetic Medicine

Volumn 25, Issue 11, 2008, Pages 1349-1353

  Antonelli, A ^a   Fallahi, P ^a   Ferrari, S M ^a   Pupilli, C ^b   D'Annunzio, G ^c   Lorini, R ^c   Vanelli, M ^d   Ferrannini, E ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

chemokine monocyte chemoattractant protein 1; Interferon inducible chemokine inducing protein 10; T helper 1; T helper 2; Type 1 diabetes

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATHOPHYSIOLOGY; SERUM;

CHEMOKINE CCL2; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-10; LONGITUDINAL STUDIES; MALE; RECEPTORS, CHEMOKINE; ROC CURVE; TH1 CELLS; TIME FACTORS;

EID: 55149086806     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02577.x     Document Type: Article

References (11)

1. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O et al. Elevated serum IP-10 levels observed in Type 1 diabetes. Diabetes Care 2001 24 : 510 515.
2. Suzuki R, Shimada A, Maruyama T, Funae O, Morimoto J, Kodama K et al. T-cell function in anti-GAD65(+) diabetes with residual beta-cell function. J Autoimmun 2003 20 : 83 90.
3. Nicoletti F, Conget I, Di Mauro M, Di Marco R, Mazzarino MC, Bendtzen K et al. Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002 45 : 1107 1110.
4. Christen U. Chemokines as drug targets in Type 1 diabetes. Endocr Metab Immune Disord Drug Targets 2007 7 : 7 12.
5. Antonelli A, Tuomi T, Nannipieri M, Fallahi P, Nesti C, Okamoto H et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002 45 : 1298 1306.
6. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antagonist in Type 2 diabetes mellitus. N Engl J Med 2007 356 : 1517 1526.
7. Hanifi-Moghaddam P, Kappler S, Seissler J, Müller-Scholze S, Martin S, Roep BO et al. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med 2006 23 : 156 163.
8. Lohmann T, Laue S, Nietzschmann U, Kapellen TM, Lehmann I, Schroeder S et al. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of Type 1 diabetes. Diabetes 2002 51 : 2474 2480.
9. Cipollone F, Chiarelli F, Davì G, Ferri C, Desideri G, Fazia M et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005 48 : 1216 1224.
10. Kiyici S, Erturk E, Budak F, Ersoy C, Tuncel E, Duran C et al. Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in Type 1 diabetic patients with nephropathy. Arch Med Res 2006 37 : 998 1003.
11. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000 58 : 684 690.